News|Articles|July 12, 2017

Andropharm Recalls Sten Z and M1 Alpha Capsules

The company is voluntarily recalling Sten Z and M1 Alpha capsules because the product contains derivatives of anabolic steroids, which makes them unapproved drugs.

On July 11, 2017, Andropharm announced it was voluntarily recalling all lots of Sten Z and M1 Alpha capsules to the consumer level. The products have been rendered unapproved drugs because they contain derivatives of anabolic steroids and have not been tested for their safety and efficacy. The recalled products were packaged as capsules in 60-count bottles with the UPC code-642125502948(Sten Z) and UPC code-642125502924(M1 Alpha). They were sold through retailers nationwide in the United States from March 2016 to April 2017. This recall applies to all lot numbers and expiration dates of these products.

According to the company, use of the recalled products may cause elevated blood pressure, aggressive behavior, male infertility, or enlarged breasts and shrinkage of the testes in men. The risk of adverse reaction is greater in people with underlying cardiac, hepatic, or prostate conditions. The company has not received any reports of adverse events associated with the recalled products as of the date of the recall.

Consumers should discontinue use of the product. Adverse events can be reported to FDA via its website. 

Source: FDA


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.